Patent arteriovenous fistulas did not significantly affect cardiovascular abnormalities such as left ventricular hypertrophy and left ventricular mass index in renal transplant recipients.
Observational (n=130)
Does a patent arteriovenous fistula contribute to persistent left ventricular hypertrophy in renal allograft recipients?
Patent arteriovenous fistulas do not appear to contribute to persistent left ventricular hypertrophy or other cardiovascular abnormalities in renal transplant recipients.
Purpose Left ventricular hypertrophy (LVH) is frequently observed in patients with end-stage renal disease and renal allograft recipients, and is an independent and strong predictor of morbidity and mortality. Presence of a patent arteriovenous fistula (AVF) after renal transplantation may contribute to the persistent LVH. We investigated the clinical, laboratory, and echocardiographic findings in patients with renal transplants with or without AVF. Methods A total of 130 renal transplant recipients were included in this study: 60 hemodialysis patients whose fistulas were still functional, 49 hemodialysis patients whose fistulas were spontaneous stopped or closed, and 21 peritoneal dialysis patients who had never had fistulas created. Laboratory parameters were measured and echocardiographic measurements were performed. Results There were no significant differences regarding smoking status, blood pressures, or NT-proBNP, hs-CRP, iPTH, and TSH levels between the study groups. Left atrial, right atrial diameters, left ventricle end-diastolic diameter, left ventricle end-systolic diameter, interventricular septum thickness (IVST), left ventricle mass index (LVMI), pulmonary artery pressure (PAP), and ejection fraction were similar in the three groups. In correlation analysis, PAP was significantly correlated with serum uric acid and NT-proBNP levels. Also, there were positive and moderate correlations between the serum uric acid and the IVST. Conclusion Patent AVFs have not affected cardiovascular abnormalities such as LVH and LV mass index in patients with renal transplant. Hyperuricemia may be associated with increased PAP and high LVMI.
Görgülü et al. (Sat,) conducted a observational in Renal allograft recipients (n=130). Patent arteriovenous fistula vs. Closed AVF or no history of AVF was evaluated on Clinical, laboratory, and echocardiographic findings including LVH and LV mass index. Patent arteriovenous fistulas did not significantly affect cardiovascular abnormalities such as left ventricular hypertrophy and left ventricular mass index in renal transplant recipients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: